Mechanism research of dexmedetomidine in the treatment of postherpetic neuralgia by promoting MDSC apoptosis and inhibiting p75

Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•(1) those who meet the diagnostic criteria for postherpetic neuralgia
•(2) aged 18 to 80 years;
•(3) body mass index (BMI) ranged from 18.0 to 25.0 (including 18.0 years old and 25.0 years old);
•(4) VAS score of 4-10 points (including 4 points and 10 points);
•(5) no satisfactory remission for at least 1 month after conservative pain treatment (e.g., antidepressants, anticonvulsants, tramadol, opioids, nerve block or damage, radiofrequency conditioning or damage);
•(6) voluntarily participate in the study and have signed the informed consent.

•(1) people who are known to be allergic to dexmedetomidine and ketorolac amantinol;
•(2) inability to cooperate, such as lethargy, coma, confusion, delirium;
•(3) having a history of alcohol or drug abuse;
•(4) participants who have participated in other clinical trials within 12 weeks prior to or before the trial;
•(5) patients with pain syndrome (such as complex regional pain syndrome, spinal cord injury, diabetic multiple neuropathy, fibromyalgia);
•(6) patients with severe systemic diseases (including hypertension grade 2 or above, diabetes, myasthenia gravis, severe renal impairment, severe pulmonary dysfunction, shock, severe liver dysfunction, acute heart failure);
•(7) patients with infectious diseases (i.e. HIV, hepatitis b, syphilis);
•(8) severely infected;
•(9) patients with malignant tumors;
•(10) mental disorders (such as somatization disorders, schizophrenia, mania);
•(11) resting heart rate < 55 times/min or > 100 times/min after ecg screening.

发起方

Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University